SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today it ranked number 42 on Deloitte’s Technology Fast 500, a ranking of the five hundred fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Trius’ revenues grew 3,420 percent during the five year period ending 2011. Last year, Trius was ranked number 226 on the Fast 500 list.
